Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MW-III vs Silver Sulfadiazine in Thermal Burns
NCT01297400Phase 2Recruiting
- Sponsor
- Skingenix, Inc.
- Start
- Mar 2022
- Primary completion
- Dec 2026
- Modality
- Botanical drug
- Countries
- 2
01
Overview
A Phase 2 trial of MW-III in thermal burn, sponsored by Skingenix, Inc.. Started Mar 2022; status: recruiting.
02
Drugs
MW-III
03
Conditions
thermal burn
Beyond the preview
Go deeper on NCT01297400.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01297400.